SGO2 and hepatocellular carcinoma: SGOL2 overexpression was closely related to poor overall survival (HR = 2.29 (1.6–3.28), P = 3.5e-06), relapse-free survival (HR = 1.96 (1.38–2.78), P = 0.00013), progression-free survival (HR = 2.1 (1.55–2.84), P = 9.2e-07) and disease-specific survival (HR = 2.84 (1.81–4.47), P = 2.3e-06) in HCC patients (Fig. 1G, Fig. S4A-C).